Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.

Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Petersen JA, De Haas S, Hoersch S, Patre M, Ellis PA.

Cancer. 2019 Jul 18. doi: 10.1002/cncr.32392. [Epub ahead of print]

PMID:
31318460
2.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA.

BMC Cancer. 2019 Jun 24;19(1):620. doi: 10.1186/s12885-019-5831-x.

3.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA.

BMC Cancer. 2019 May 30;19(1):517. doi: 10.1186/s12885-019-5687-0. Erratum in: BMC Cancer. 2019 Jun 24;19(1):620.

4.

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL.

Gastric Cancer. 2019 Jul;22(4):803-816. doi: 10.1007/s10120-018-00923-7. Epub 2019 Jan 31.

PMID:
30706247
5.

Maternal kidney function during pregnancy: systematic review and meta-analysis.

Lopes van Balen VA, van Gansewinkel TAG, de Haas S, Spaan JJ, Ghossein-Doha C, van Kuijk SMJ, van Drongelen J, Cornelis T, Spaanderman MEA.

Ultrasound Obstet Gynecol. 2019 Sep;54(3):297-307. doi: 10.1002/uog.20137. Epub 2019 Aug 6. Review.

6.

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE.

Clin Cancer Res. 2019 Jan 1;25(1):64-72. doi: 10.1158/1078-0432.CCR-18-1590. Epub 2018 Sep 11.

PMID:
30206164
7.

Dietary patterns and changes in frailty status: the Rotterdam study.

de Haas SCM, de Jonge EAL, Voortman T, Graaff JS, Franco OH, Ikram MA, Rivadeneira F, Kiefte-de Jong JC, Schoufour JD.

Eur J Nutr. 2018 Oct;57(7):2365-2375. doi: 10.1007/s00394-017-1509-9. Epub 2017 Jul 25.

8.

Physiological adaptation of endothelial function to pregnancy: systematic review and meta-analysis.

Lopes van Balen VA, van Gansewinkel TAG, de Haas S, van Kuijk SMJ, van Drongelen J, Ghossein-Doha C, Spaanderman MEA.

Ultrasound Obstet Gynecol. 2017 Dec;50(6):697-708. doi: 10.1002/uog.17431. Review.

9.

Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis.

de Haas S, Ghossein-Doha C, van Kuijk SM, van Drongelen J, Spaanderman ME.

Ultrasound Obstet Gynecol. 2017 Feb;49(2):177-187. doi: 10.1002/uog.17360. Review.

10.

Source tracking of Enterococcus moraviensis and E. haemoperoxidus.

Taučer-Kapteijn M, Hoogenboezem W, Hoogenboezem R, de Haas S, Medema G.

J Water Health. 2017 Feb;15(1):41-49. doi: 10.2166/wh.2016.209.

PMID:
28151438
11.

Cardiac remodeling in normotensive pregnancy and in pregnancy complicated by hypertension: systematic review and meta-analysis.

De Haas S, Ghossein-Doha C, Geerts L, van Kuijk SMJ, van Drongelen J, Spaanderman MEA.

Ultrasound Obstet Gynecol. 2017 Dec;50(6):683-696. doi: 10.1002/uog.17410. Review.

12.

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.

Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, Chang JC, Patre M, Strasak A, de Haas SL, Xu J, Garcia-Saenz JA.

Ann Oncol. 2016 Jul;27(7):1249-56. doi: 10.1093/annonc/mdw157. Epub 2016 Apr 6.

PMID:
27052654
13.

Lesbian, Gay, and Bisexual Adults: Childhood Gender Nonconformity, Childhood Trauma, and Sexual Victimization.

Bos H, de Haas S, Kuyper L.

J Interpers Violence. 2019 Feb;34(3):496-515. doi: 10.1177/0886260516641285. Epub 2016 Apr 1.

PMID:
27036153
14.

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.

Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino AE, Samant MK, Olsen S, de Haas SL, Pegram MD.

Clin Cancer Res. 2016 Aug 1;22(15):3755-63. doi: 10.1158/1078-0432.CCR-15-2499. Epub 2016 Feb 26. Erratum in: Clin Cancer Res. 2018 Nov 1;24(21):5486.

15.

89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.

Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Hollema H, de Jong JR, de Jong IJ, de Haas S, Scherer SJ, Sluiter WJ, Dierckx RA, Bongaerts AH, Gietema JA, de Vries EG.

J Nucl Med. 2015 Jan;56(1):63-9. doi: 10.2967/jnumed.114.144840. Epub 2014 Dec 4.

16.

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.

de Haas S, Delmar P, Bansal AT, Moisse M, Miles DW, Leighl N, Escudier B, Van Cutsem E, Carmeliet P, Scherer SJ, Pallaud C, Lambrechts D.

Angiogenesis. 2014 Oct;17(4):909-20. doi: 10.1007/s10456-014-9438-1. Epub 2014 Jul 11.

PMID:
25012543
17.

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

Miller KD, Diéras V, Harbeck N, Andre F, Mahtani RL, Gianni L, Albain KS, Crivellari D, Fang L, Michelson G, de Haas SL, Burris HA.

J Clin Oncol. 2014 May 10;32(14):1437-44. doi: 10.1200/JCO.2013.52.6590. Epub 2014 Apr 14.

PMID:
24733796
18.

Genetic markers of bevacizumab-induced hypertension.

Lambrechts D, Moisse M, Delmar P, Miles DW, Leighl N, Escudier B, Van Cutsem E, Bansal AT, Carmeliet P, Scherer SJ, de Haas S, Pallaud C.

Angiogenesis. 2014 Jul;17(3):685-94. doi: 10.1007/s10456-014-9424-7. Epub 2014 Feb 21.

PMID:
24558090
19.

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR, Scherer SJ.

Br J Cancer. 2013 Mar 19;108(5):1052-60. doi: 10.1038/bjc.2013.69. Epub 2013 Feb 19.

20.

Markers of response for the antiangiogenic agent bevacizumab.

Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ.

J Clin Oncol. 2013 Mar 20;31(9):1219-30. doi: 10.1200/JCO.2012.46.2762. Epub 2013 Feb 11. Review.

PMID:
23401453
21.
22.

Orexin receptor antagonism: an ascending multiple-dose study with almorexant.

Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J.

J Psychopharmacol. 2012 Aug;26(8):1071-80. doi: 10.1177/0269881112448946. Epub 2012 Jun 13.

PMID:
22695489
23.

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.

Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, Van Cutsem E.

Lancet Oncol. 2012 Jul;13(7):724-33. doi: 10.1016/S1470-2045(12)70231-0. Epub 2012 May 17.

PMID:
22608783
24.

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.

Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA.

J Clin Oncol. 2012 Jun 10;30(17):2119-27. doi: 10.1200/JCO.2011.39.9824. Epub 2012 May 7.

PMID:
22565005
25.

An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists.

Chen X, de Haas S, de Kam M, van Gerven J.

Adv Pharmacol Sci. 2012;2012:134523. doi: 10.1155/2012/134523. Epub 2012 Jan 29.

26.

The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol.

de Haas SL, Zoethout RW, Van Dyck K, De Smet M, Rosen LB, Murphy MG, Gottesdiener KM, Schoemaker RC, Cohen AF, van Gerven JM.

J Psychopharmacol. 2012 Feb;26(2):282-91. doi: 10.1177/0269881111415731. Epub 2011 Sep 2.

PMID:
21890585
27.

A case of intrathoracic stomach and spleen after aortic repair: an unusual complication.

de Haas SA, van der Weijden PK, Steenvoorde P, Joosten PP.

J Clin Med Res. 2010 May 19;2(3):140-1. doi: 10.4021/jocmr2010.04.293w.

28.

Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant.

Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, Dingemanse J.

Clin Pharmacol Ther. 2010 May;87(5):593-600. doi: 10.1038/clpt.2010.19. Epub 2010 Apr 7.

PMID:
20376002
29.

Relations among temperament, parenting and problem behavior in young children.

Karreman A, de Haas S, van Tuijl C, van Aken MA, Deković M.

Infant Behav Dev. 2010 Feb;33(1):39-49. doi: 10.1016/j.infbeh.2009.10.008. Epub 2009 Dec 3.

PMID:
19962197
30.

Sexual harassment and health among male and female police officers.

de Haas S, Timmerman G, Höing M.

J Occup Health Psychol. 2009 Oct;14(4):390-401. doi: 10.1037/a0017046.

PMID:
19839659
31.

Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects.

de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J.

J Psychopharmacol. 2010 Nov;24(11):1619-29. doi: 10.1177/0269881109106898. Epub 2009 Jul 31.

PMID:
19648220
32.

The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers.

de Haas SL, Franson KL, Schmitt JA, Cohen AF, Fau JB, Dubruc C, van Gerven JM.

J Psychopharmacol. 2009 Aug;23(6):625-32. doi: 10.1177/0269881108092595. Epub 2008 Jul 17.

PMID:
18635696
33.

MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers.

Boot JD, De Haas SL, Van Gerven JM, De Smet M, Leathem T, Wagner J, Denker A, Miller D, Van Doorn MB, Schoemaker RC, Cohen AF, Diamant Z.

Pulm Pharmacol Ther. 2008;21(3):573-7. doi: 10.1016/j.pupt.2008.01.009. Epub 2008 Feb 3.

PMID:
18321743
34.

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.

de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, de Smet M, Vessey LK, Ramakrishnan R, Xue L, Cohen AF, van Gerven JM.

J Psychopharmacol. 2008 Jan;22(1):24-32. doi: 10.1177/0269881107082108.

PMID:
18187530
35.

Pseudohallucinations after zolpidem intake: a case report.

de Haas S, Dingemanse J, Hoever P, Cohen A, van Gerven J.

J Clin Psychopharmacol. 2007 Dec;27(6):728-30. No abstract available.

PMID:
18004155
36.

Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy.

de Haas S, Otte A, de Weerd A, van Erp G, Cohen A, van Gerven J.

J Clin Sleep Med. 2007 Aug 15;3(5):473-8.

37.

Promotion of sleep by targeting the orexin system in rats, dogs and humans.

Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F.

Nat Med. 2007 Feb;13(2):150-5. Epub 2007 Jan 28.

PMID:
17259994
38.

Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma.

Boot JD, de Haas S, Tarasevych S, Roy C, Wang L, Amin D, Cohen J, Sterk PJ, Miller B, Paccaly A, Burggraaf J, Cohen AF, Diamant Z.

Am J Respir Crit Care Med. 2007 Mar 1;175(5):450-7. Epub 2006 Dec 14.

PMID:
17170385
39.

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.

de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, Cohen AF, Vega JM, Agrawal NG, Goel TV, Simpson RC, Pearson LK, Li S, Hesney M, Murphy MG, van Gerven JM.

J Psychopharmacol. 2007 Jun;21(4):374-83. Epub 2006 Nov 8.

PMID:
17092968
40.

Subjective sleep disturbance in patients with partial epilepsy: a questionnaire-based study on prevalence and impact on quality of life.

de Weerd A, de Haas S, Otte A, Trenité DK, van Erp G, Cohen A, de Kam M, van Gerven J.

Epilepsia. 2004 Nov;45(11):1397-404.

41.

P-selectin as a candidate target in atherosclerosis.

Molenaar TJ, Twisk J, de Haas SA, Peterse N, Vogelaar BJ, van Leeuwen SH, Michon IN, van Berkel TJ, Kuiper J, Biessen EA.

Biochem Pharmacol. 2003 Sep 1;66(5):859-66.

PMID:
12948867
42.

Specific inhibition of P-selectin-mediated cell adhesion by phage display-derived peptide antagonists.

Molenaar TJ, Appeldoorn CC, de Haas SA, Michon IN, Bonnefoy A, Hoylaerts MF, Pannekoek H, van Berkel TJ, Kuiper J, Biessen EA.

Blood. 2002 Nov 15;100(10):3570-7. Epub 2002 Jul 5.

43.

Uptake and processing of modified bacteriophage M13 in mice: implications for phage display.

Molenaar TJ, Michon I, de Haas SA, van Berkel TJ, Kuiper J, Biessen EA.

Virology. 2002 Feb 1;293(1):182-91.

45.

High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.

Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, Balment RJ, Webb DJ.

Cardiovasc Res. 2002 Feb 1;53(2):341-7.

PMID:
11827684

Supplemental Content

Loading ...
Support Center